QLGN 0.18 Qualigen Therapeutics, Inc.
| Range: | 0.141-0.9 | Vol Avg: | 382234 | Last Div: | 0 | Changes: | 0.01 |
| Beta: | 0.07 | Cap: | 0.00B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Tue Jun 23 2015 | Empoloyees: | 4 | ||
| CUSIP: | 74754R103 | CIK: | 0001460702 | ISIN: | US74754R2022 | Country: | US |
| CEO: | Mr. Kevin A. Richardson II | Website: | https://www.qualigeninc.com | ||||
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Stock Details
Positive 0.23
Qualigen Therapeutics, Inc. Announces management changes.
CARLSBAD, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: ...
globenewswire.com·Thu Sep 26 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow